Clinical trial
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
NCT05409235 is registered in ClinicalTrials.gov with OcuTerra Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- July 29, 2022
- Completion date
- December 29, 2023
- Enrollment
- 225 (actual)
- Sites
- 68
Conditions
As the registry lists them; a condition with its own page is linked.